24 November 2025 | 12:15PM GMT Equity Research Novo Nordisk (NOVOb.CO): EVOKE/EVOKE+ miss in Alzheimer's - disappointing but not significantly impactful This morning (November 24th), Novo announced that the EVOKE/EVOKE+ trials of semaglutide in Alzheimer's disease did not hit the primary endpoint, as no efficacy difference was seen between the treatment and placebo arms, leading to the 1-year extension study to be discontinued. Topline results will be presented at the CTAD conference on December 3rd, and No ...

Market Overview - U.S. stock futures increased on Monday, continuing Friday's gains, driven by optimism regarding a potential December rate cut suggested by New York Fed President John Williams [1] - The Dow Jones Industrial Average rose 0.44% to 46,448.27, the S&P 500 increased by 1.5% to 6,705.12, and the Nasdaq jumped 2.69% to 22,872.00 [1] Semiconductor Sector - The semiconductor sector experienced a boost as hopes for a December Fed rate cut lifted tech stocks, with supportive comments from Federal Reserve Governor Christopher Waller further fueling the rally [2] Broadcom Inc. - Broadcom's stock surged 11.10% to close at $377.96, reaching an intraday high of $382 and a low of $347.66, with a 52-week high of $386.48 and a low of $138.10; in after-hours trading, the stock rose 1.49% to $383.60 [1] Alphabet Inc. - Alphabet's Class C shares climbed 6.28% to close at $318.47, hitting a new 52-week high of $319.80, with a low of $142.66; after-hours trading saw a gain of 2.65% to $326.90 [3][4] - Alphabet's Class A shares ended the day 6.3% higher at $318.58, gaining 2.6% to $327 in extended trading [3] - The company is reportedly in talks with Meta and other cloud clients to supply Google's AI TPU chips, indicating increased competition with Nvidia; Alphabet shares rose about 2% after-hours while Nvidia slipped roughly 2% [4] SanDisk Corporation - SanDisk's stock rose 13.33% to $226.96, with a high of $228.18 and a low of $205.13; the stock's 52-week high is $284.76 and a low of $27.90, popping 7.29% to $243.50 in after-hours trading [5][6] - SanDisk was added to the S&P 500, replacing Interpublic Group after its acquisition by Omnicom, effective November 28; PTC Therapeutics will replace SanDisk in the S&P SmallCap 600 [6] - The company reported strong fourth-quarter results on November 6, beating revenue and EPS estimates for the eighth time in ten quarters [6] Novo Nordisk A/S - Novo Nordisk shares fell 5.58% to $44.97, with a high of $45.22 and a low of $43.08; the stock's 52-week high is $112.52 [7][8] - The company reported that its 2-year evoke and evoke+ trials did not show semaglutide to be superior to placebo in slowing Alzheimer's disease progression, despite improvements in biomarkers; the 1-year extension phase will be discontinued [8] Zoom Communications Inc. - Zoom's stock dipped slightly by 0.04% to close at $78.60, with an intraday high of $80.27 and a low of $78.59; the stock's 52-week high is $92.80 [10][11] - The company reported third-quarter revenue of $1.23 billion and adjusted earnings of $1.52 per share, beating forecasts; enterprise revenue rose 6.1% year-over-year, ending the quarter with 4,363 large customers and generating $629.3 million in operating cash flow [11]

Core Viewpoint - Novo Nordisk has been downgraded by HSBC from "Buy" to "Hold" as its stock price approaches a four-year low, primarily due to disappointing trial results for its Alzheimer's drug, semaglutide [1][6]. Group 1: Stock Performance - The stock has fallen sharply by 7.8% to $43.87, nearing a four-year low of $43.37, and has lost 58% of its value since reaching a record high of $148.15 in June 2024 [2][4]. - Currently, the stock price stands at $44.39, reflecting a decrease of approximately 6.80%, with fluctuations between $43.08 and $47.02 today, and a market capitalization of about $197.3 billion [5]. Group 2: Trial Results Impact - The failure of oral semaglutide in phase 3 trials for Alzheimer's disease has significantly impacted Novo Nordisk, as the trials did not meet expected outcomes, adversely affecting share price and market sentiment [4][6]. Group 3: Investor Sentiment - Despite the challenges, there is increased activity among call traders, with a 10-day call/put volume ratio of 5.75 reported by the International Securities Exchange, indicating some investor optimism for a potential rebound or hedging against further declines [3].

Novo Nordisk reported results Monday for its trial to determine whether the active ingredient in Ozempic and Wegovy could slow the progression of Alzheimer's. Sergei Gapon / AFP / Getty Images Close Key Takeaways Novo Nordisk (NVO) shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial. The company had been looking to determine whether semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, could also slow the cognitive decline associated wit ...

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Monday's key moments. 1. The S & P 500 and Nasdaq each surged Monday on the back of Alphabet 's gains and expectations for a third Fed interest rate in 2025. Shares of the Google parent jumped more than 4% on excitement about the launch of Gemini 3, which also sparked debate about whether it is superior to OpenAI's ChatGPT. Jim Cramer said, "The rate cut story is really behind a lot ...

Novo Nordisk A/S ( NVO ) shocked the market once again with a major drop on the news that its semaglutide didn’t prove to slow the progression of Alzheimer's disease:I write about stocks I’m personally interested in adding to my portfolio. I’m not a professional advisor, but I study business and economics and analyze markets full-time. My writing is meant for both complete beginners — I avoid unnecessary complexity — and advanced readers, as I always aim to offer a distinct and well-reasoned perspective.I a ...

Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world to join the exclusive club dominated by technology companies. Buoyed by unprecedented demand for its weight loss drugs, the US drugmaker hit the trillion-dollar mark for the total value of its shares on 21 November. Share price in Lilly closed at $1,059.70 on 21 November, reflecting a 27% increase since January 2025. By trading at market open 24 November, share prices retreated slightl ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Drug maker Novo Nordisk (NYSE:NVO) is sinking 7.8% to trade at $43.87 this morning, earlier hitting a more than four-year low of $43.37 after sharing disappointing trial data for its Alzheimer's drug, semaglutide. The oral medication failed to pare back progression in the memory-loss disease. NVO has been on a steep, downward trajectory since topping out at a record high of $148.15 in June of 2024. The 120-day moving average has loomed as overhead resistance, capping several breakout attempts this past year ...

Core Insights - Novo Nordisk's Alzheimer's trials for an older oral version of semaglutide did not succeed in slowing the progression of the disease, marking a significant setback for the company [1] Group 1 - The trials were closely monitored and aimed at addressing Alzheimer's disease, a major health concern [1] - The failure of these trials represents a blow to Novo Nordisk's efforts in expanding its drug portfolio beyond diabetes treatments [1]